# A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

> **NCT01377376** · PHASE3 · TERMINATED · sponsor: **Kyowa Kirin Co., Ltd.**

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** ARQ 197 and Erlotinib
- **DRUG:** Placebo and Erlotinib

## Key facts

- **NCT ID:** NCT01377376
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01377376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01377376, "A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01377376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*